Neuroprotective Effects of Insulin-Like Growth Factor-Binding Protein Ligand Inhibitors in Vitro and in Vivo
Open accessThe DOI matches its Crossref record.
Abstract
The role of brain insulin-like growth factors (IGFs) and IGF binding proteins (IGFBPs) in neuroprotection was further investigated using in vitro and in vivo models of cerebral ischemia by assessing the effects of IGF-I, IGF-II, and high affinity IGFBP ligand inhibitors (the peptide [Leu 24, 59, 60, Ala 31]hIGF-I (IGFBP-LI) and the small molecule NBI-31772 (1-(3,4-dihydroxybenzoyl)-3-hydroxycarbonyl-6, 7-dihydroxyisoquinoline), which pharmacologically displace and elevate endogenous, bioactive IGFs from IGFBPs. Treatment with IGF-I, IGF-II, or IGFBP-LI (2 μg/mL) significantly ( P < 0.05) reduced CA1 damage in organotypic hippocampal cultures resulting from 35 minutes of oxygen and glucose deprivation by 71%, 60%, and 40%, respectively. In the subtemporal middle cerebral artery occlusion (MCAO) model of focal ischemia, intracerebroventricular (icv) administration of IGF-I and IGF-II at the time of artery occlusion reduced ischemic brain damage in a dose-dependent manner, with maximum reductions in total infarct size of 37% ( P < 0.01) and 38% ( P < 0.01), respectively. In this model of MCAO, icv administration of NBI-31772 at the time of ischemia onset also dose-dependently reduced infarct size, and the highest dose (100 μg) significantly reduced both total (by 40%, P < 0.01) and cortical (by 43%, P < 0.05) infarct volume. In the intraluminal suture MCAO model, administration of NBI-31772 (50 μg icv) at the time of artery occlusion reduced both cortical infarct volume (by 40%, P < 0.01) and brain swelling (by 24%, P < 0.05), and it was still effective when treatment was delayed up to 3 hours after the induction of ischemia. These results further define the neuroprotective properties of IGFs and IGFBP ligand inhibitors in experimental models of cerebral ischemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Malberg, J. E., Platt, B., Rizzo, S. J. S., Ring, R. H., Lucki, I., Schechter, L. E., & Rosenzweig-Lipson, S. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301358 · Cited by 101
“In vivo, NBI-31772 produces neuroprotective effects in a similar manner to exogenously administered IGF-I (Mackay et al, 2003).”
BackgroundInfluentialIGF2 in memory, neurodevelopmental disorders, and neurodegenerative diseases
Alberini, C. M. (2023) · Trends in Neurosciences · doi:10.1016/j.tins.2023.03.007 · Cited by 89
Teixeira, F. G., Panchalingam, K. M., Anjo, S. I., Manadas, B., Pereira, R., Sousa, N., Salgado, A. J., & Behie, L. A. (2015) · Stem Cell Research & Therapy · doi:10.1186/s13287-015-0124-z · Cited by 87
“oxic hWJ-MSC CM) are known for their roles in the enhancement of neuroprotection, axonal growth, neurite outgrowth and neuronal cell survival and differentiation [90–99].”
BackgroundCirculating IGFBP‐2: a novel biomarker for incident dementia
McGrath, E. R., Himali, J. J., Levy, D., Conner, S. C., DeCarli, C. S., Pase, M. P., Courchesne, P., Satizabal, C. L., Vasan, R. S., Beiser, A. S., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50854 · Cited by 49
Metadata
- Authors
- Mackay, K. B., Loddick, S. A., Naeve, G. S., Vana, A. M., Verge, G. M., & Foster, A. C.
- Venue
- Journal of Cerebral Blood Flow & Metabolism
- Publisher
- SAGE Publications
- Published
- 2003-10
- Volume
- 23
- Issue
- 10
- Pages
- 1160-1167
- ISSN
- 0271-678X (ISSN-L)
- 1559-7016
- OpenAlex
- W2042040005
- Cited by
- 59
- References
- 0
- FWCI
- 2.78
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neuroprotective Effects of Insulin-Like Growth Factor-Binding Protein Ligand Inhibitors in Vitro and in Vivo. https://app.cochat.ai/papers/10.1097/01.wcb.0000087091.01171.ae
- The paper
- Mackay, K. B., Loddick, S. A., Naeve, G. S., Vana, A. M., Verge, G. M., & Foster, A. C. (2003). Neuroprotective Effects of Insulin-Like Growth Factor-Binding Protein Ligand Inhibitors in Vitro and in Vivo. Journal of Cerebral Blood Flow & Metabolism. https://doi.org/10.1097/01.wcb.0000087091.01171.ae
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.